Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Prior treatment

• Participants with chronic or ongoing steroid or immunomodulatory agents (i.e., prednisone, dexamethasone, etanercept, infliximab, etc.). The use of glucocorticoids as pre-medications for chemotherapy treatment is allowed.

Other illness

• Currently enrolled in an interventional supportive treatment trial to manage cancer symptoms.
• Participant received systemic therapy treatment for prior cancer(s) including chemotherapy, immunotherapy, targeted therapy, and hormonal therapy.
• Participants with a history of HIV, hepatitis B or hepatitis C.

Other

• Participants with known pregnancy.
• Participants enrolled in hospice.
  • Optional Substudy (available at select sites only):

• Adults aged 18 years or older with one of the following newly diagnosed cancers: breast cancer, colorectal cancer, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer (e.g. adenocarcinoma, squamous cell carcinoma, large cell carcinoma, adenosquamous cell carcinoma, and not otherwise specified).
• Planned treatment with systemic chemotherapy (single or multi-agent, includes targeted therapy) and/or immune checkpoint inhibitor therapy (targeting PD-1, PD-L1 or CTLA-4). If unable to engage participant before treatment starts, enrollment is allowed up to the start of Cycle 2 treatment.
• Participants must be able to comprehend English or Spanish (for survey completion).
• Participants must have a working email address and be must be willing to complete surveys online. This can be completed at home, in the clinic or other location.
• Completion of the confidential Self-Reported Screening Survey and receipt of a screening result - eligible for enrollment.
• Participant must reside in the United States, officially determined per patient report on Self-reported Screening Survey
• In the treating provider's opinion, the participant should have a life expectancy of \>=6 months. Participants in hospice are not eligible.
  • Optional Sub-study (available at select sites only):
• Must be willing to participate in both the main study and the sub-study at the Wake Forest University Comprehensive Cancer Center (WF CCC) and Virginia Commonwealth University (VCU).
• Must be receiving treatment at the WF CCC and VCU.
• Must be planning to receive Immune Checkpoint Inhibitor (ICIs) targeting PD-1, PD-L1 or CTLA-4.